REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL). 13. Juli 2020 Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020. HemaSphere 4(S1) (EP1245), 583. REFLECT real-world evidence (RWE) prospective study update: Efficacy and safety results of Sandoz biosimilar rituximab (SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL). Welslau M, Marschner N, Otremba B, Topaly J, Bittencourt da Silva L, 2020. J Clin Oncol 38 no. 15_suppl (May 20, 2020) 8060-8060. DOI:… Weiterlesen Rare patients in routine care: Treatment and outcome in advanced invasive lobular breast cancer in the prospective German research platform OPAL Thill M., Zahn M.-O., Welt A., Stickeler E., Nusch A., Fietz T., Rauh J., Wetzel N., Kruggel L., Jänicke M., Marschner N., Harbeck N., Wöckel… Weiterlesen